Biomedical Engineering Reference
In-Depth Information
189. Mizuarai S, Aozasa N, Kotani H. 2004. Single nucleotide polymorphisms result in
impaired membrane localization and reduced atpase activity in multidrug transporter
ABCG2. Int J Cancer 109: 238-246.
190. Morisaki K, Robey RW, Ozvegy-Laczka CS, Honjo Y, Polgar O, Steadman K, Sarkadi
B, Bates SE. 2005. Single nucleotide polymorphisms modify the transporter activity of
ABCG2. Cancer Chemother Pharm 56: 161-172.
191. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves
C, Verweij J, McLeod HL. 2004. Diflomotecan pharmacokinetics in relation to ABCG2
421C>A genotype. Clin Pharmacol Ther 76: 38-44.
192. Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, Figg WD, Nooter K,
Gelderblom H. 2005. Effect of ABCG2 genotype on the oral bioavailability of topotecan.
Cancer Biol Ther 4: 650-658.
193. Ozvegy-Laczka C, Cserepes J, Elkind NB, Sarkadi B. 2005. Tyrosine kinase inhibitor
resistance in cancer: role of ABC multidrug transporters. Drug Resist Updates 8: 15-26.
194. Elkind NB, Szentpetery Z, Apati A, Ozvegy-Laczka C, Varady G, Ujhelly O, Szab´oK,
Homolya L, Varadi A, Buday L. et al. 2005. Multidrug transporter ABCG2 prevents tumor
cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839,
Gefitinib). Cancer Res 65: 1770-1777.
195. Shih YN, Chiu CH, Tsai CM, Perng RP. 2005. Interstitial pneumonia during gefitinib
treatment of non-small-cell lung cancer. J Chin Med Assoc 68: 183-186.
196. Schellens JHM, Creemers GJ, Beijnen JH, Rosing H, de Boer-Dennert M, McDonald M,
Davies B, Verweij J. 1996. Bioavailability and pharmacokinetics of oral topotecan: a new
topoisomerase I inhibitor. Br J Cancer 73: 1268-1271.
197. Schellens JHM, Maliepaard M, Scheper RJ, Scheffer GL, Jonker JW, Smit JW, Bei-
jnen JH, Schinkel AH. 2000. Transport of topoisomerase I inhibitors by the breast
cancer resistance protein: potential clinical implication. Ann Acad Sci 922: 188-
194.
198. Zamboni WC, Bowman LC, Tan M, Santana VM, Houghton PJ, Meyer WH, Pratt CB,
Heideman RL, Gajjar AJ, Pappo AS, Stewart CF. 1999. Interpatient variability in bioavail-
ability of the intravenous formulation of topotecan given orally to children with recurrent
solid tumors. Cancer Chemother Pharmacol 6: 454-460.
199. Nakatomi K, Yshikawa M, Oka M, Ikegami Y, Hayasaka S, Sano K, Shiozawa K,
Kawabata S, Soda H, Ishikawa T, Tanabe S, Kohno S. 2001. Transport of 7-ethyl-10-
hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human
lung cancer cells. Biochem Biophys Res Commun 288: 827-832.
200. Zamboni WC, Ramanathan RK, McLeod HL, Mani S, Potter DM, Strychor S, Maruca
LJ, King CR, Jung LL, Parise RA, et al. 2006. Disposition of 9-nitrocamptothecin and its
9-aminocamptothecin metabolite in relation to ABC transporters genotypes. Invest New
Drugs 24: 393-401.
201. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, Litman
T, Dean M, Bates SE. 2001. Acquired mutations in the MXR/BCRP/ABCP gene alter
substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61: 6635-
6639.
202. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS,
Bates SE. 2003. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and
antagonist specificity. Br J Cancer 89: 1971-1978.
Search WWH ::
Custom Search